Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 31 to 45 of 52 results for depression in children and adolescents

  1. Personality disorders: borderline and antisocial (QS88)

    This quality standard covers assessing and managing borderline and antisocial personality disorders. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    11 June 2015
    View quality statements

    Sections for QS88

  2. Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people (TA300)

    Evidence-based recommendations on peginterferon alfa (Pegasys; ViraferonPeg) and ribavirin (Copegus) for treating chronic hepatitis C in children and young people.

    Technology appraisal guidance
    Published
    27 November 2013
    View recommendations

    Sections for TA300

  3. Sapropterin for treating hyperphenylalaninaemia in phenylketonuria (TA729)

    Evidence-based recommendations on sapropterin for treating hyperphenylalaninaemia in phenylketonuria.

    Technology appraisal guidance
    Published
    22 September 2021
    View recommendations

    Sections for TA729

  4. Omalizumab for treating severe persistent allergic asthma (TA278)

    Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma in people aged 6 and over.

    Technology appraisal guidance
    Published
    24 April 2013
    View recommendations

    Sections for TA278

  5. Virtual reality technologies for treating agoraphobia or agoraphobic avoidance: early value assessment (HTE15)

    Early value assessment (EVA) guidance on virtual reality technologies for treating agoraphobia or agoraphobic avoidance....

    Health technology evaluation
    Published
    15 November 2023
    View recommendations

    Sections for HTE15

  6. Guided self-help digital cognitive behavioural therapy for children and young people with mild to moderate symptoms of anxiety or low mood: early value assessment (HTE3)

    Early value assessment (EVA) guidance on guided self-help digital cognitive behavioural therapy for children and young people with mild to moderate symptoms of ...

    Health technology evaluation
    Last updated
    5 September 2023
    View recommendations

    Sections for HTE3

  7. What is the clinical and cost effectiveness, post-treatment and at longer-term follow‑up, of family therapy, psychodynamic psychotherapy and interpersonal psychotherapy for adolescents (IPT‑A) compared with each other and with individual CBT in young people aged 12 to 18 years with moderate to severe depression?

    psychotherapy for adolescents (IPT‑A) compared with each other and with individual CBT in young people aged 12 to 18 years with moderate...

    Research recommendation
    Published
    25 October 2019

  8. What is the clinical and cost effectiveness, post-treatment and at longer-term follow‑up, of psychological therapies in children aged 5 to 11 years with mild or moderate to severe depression?

    follow‑up, of psychological therapies in children aged 5 to 11 years with mild or moderate to severe depression? Any...

    Research recommendation
    Published
    25 October 2019

  9. Past appeals and decisions

    adalimumab, etanercept & infliximab 31 March 2008 TA010 Asthma (children under 5) - inhaler devices 31 August 2000 TA138 Asthma (in...

  10. Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over (HST20)

    Evidence-based recommendations on selumetinib (Koselugo) for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over.

    Highly specialised technologies guidance
    Published
    5 May 2022
    View recommendations

    Sections for HST20

  11. Amantadine, oseltamivir and zanamivir for the treatment of influenza (TA168)

    Evidence-based recommendations on amantadine (Lysovir), oseltamivir (Tamiflu) and zanamivir (Relenza) for treating influenza in children and adults.

    Technology appraisal guidance
    Published
    25 February 2009
    View recommendations

    Sections for TA168

  12. Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza (TA158)

    Evidence-based recommendations on oseltamivir (Tamiflu), amantadine (Lysovir or Symmetrel) or zanamivir (Relenza) for preventing flu.

    Technology appraisal guidance
    Published
    24 September 2008
    View recommendations

    Sections for TA158

  13. Pelvic floor dysfunction: prevention and non-surgical management (NG210)

    This guideline covers the prevention, assessment and non-surgical management of pelvic floor dysfunction in women aged 12 and over. It aims to raise awareness and help women to reduce their risk of pelvic floor dysfunction. For women who have pelvic floor dysfunction, the guideline recommends interventions based on their specific symptoms.

    NICE guideline
    Published
    9 December 2021
    View recommendations

    Sections for NG210

  14. What is the clinical and cost effectiveness, post-treatment and at longer-term follow‑up, of a brief psychosocial intervention as reported by the IMPACT trial, but delivered by practitioners other than psychiatrists and in other settings, including primary care, to young people aged 12 to 18 years with mild or moderate to severe depression?

    moderate to severe depression? Any explanatory notes(if applicable) Making choices about treatments As for mild depression,...

    Research recommendation
    Published
    25 October 2019

  15. Selpercatinib for treating advanced thyroid cancer with RET alterations (TA742)

    Evidence-based recommendations on selpercatinib (Retsevmo) for advanced thyroid cancer with RET alterations in people 12 years and older.

    Technology appraisal guidance
    Published
    3 November 2021
    View recommendations

    Sections for TA742